Vaccines against stimulants: Cocaine and MA

British Journal of Clinical Pharmacology

Volumn 77, Issue 2, 2014, Pages 368-374

  Kosten, Thomas ^a,b   Domingo, Coreen ^a,b   Orson, Frank ^a,b   Kinsey, Berma ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

clinical trial; cocaine; stimulants; vaccines

Indexed keywords

ANTIBODY; BOVINE SERUM ALBUMIN; CARRIER PROTEIN; CENTRAL STIMULANT AGENT; CHOLERA TOXIN B SUBUNIT; COCAINE; COCAINE VACCINE; HAPTEN; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; ISOQUINOLINE DERIVATIVE; LIPOPOLYSACCHARIDE; METHAMPHETAMINE; METHAMPHETAMINE VACCINE; METHYLTETRAHYDROISOQUINOLINE; MONOCLONAL ANTIBODY; OVALBUMIN; PHOSPHOLIPID; PLACEBO; POLYSACCHARIDE; SUCCINIC ACID; SUCCINYLNORCOCAINE; UNCLASSIFIED DRUG; VACCINE;

ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BRAIN; CLINICAL TRIAL (TOPIC); COCAINE DEPENDENCE; DRUG ABUSE; DRUG CONJUGATION; DRUG DEPENDENCE; DRUG DESIGN; DRUG DOSE COMPARISON; DRUG MECHANISM; EUPHORIA; HUMAN; HYPERTENSION; HYPERTHERMIA; IMMUNE RESPONSE; IMMUNOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TACHYCARDIA; VACCINATION;

CLINICAL TRIAL; COCAINE; STIMULANTS; VACCINES;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; CLINICAL TRIALS AS TOPIC; COCAINE; COCAINE-RELATED DISORDERS; HAPTENS; HUMANS; IMMUNOTHERAPY; METHAMPHETAMINE; VACCINES;

EID: 84893125208     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12115     Document Type: Article

References (37)

1. United Nations Office on Drugs and Crime. World Drug Report 2010. Available at http://www.unodc.org/documents/wdr/WDR-2010/2.3-Coca-cocaine.pdf (last accessed 8 March 2012).
2. Kosten T, Owens SM,. Immunotherapy for the treatment of drug abuse. Pharmacol Ther 2005; 108: 76-85.
3. Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F,. Quantification of behavior Sackler colloquium: addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci U S A 2011; 108: 15037-15042.
4. Orson FM, Kinsey BM, Singh RA, Wu Y, Gardner T, Kosten TR,. Substance abuse vaccines. Ann N Y Acad Sci 2008; 1141: 257-269.
5. Nelson RA, Boyd SJ, Ziegelstein RC, Herning R, Cadet JL, Henningfield JE, Schuster CR, Contoreggi C, Gorelick DA,. Effect of rate of administration on subjective and physiological effects of intravenous cocaine in humans. Drug Alcohol Depend 2006; 82: 19-24.
6. Cornish JW, O'Brien CP,. Crack cocaine abuse: an epidemic with many public health consequences. Annu Rev Public Health 1996; 17: 259-273.
7. Walsh SL, Stoops WW, Moody DE, Lin SN, Bigelow GE,. Repeated dosing with oral cocaine in humans: assessment of direct effects, withdrawal, and pharmacokinetics. Exp Clin Psychopharmacol 2009; 17: 205-216.
8. Smith BJ, Jones HE, Griffiths RR,. Physiological, subjective and reinforcing effects of oral and intravenous cocaine in humans. Psychopharmacology (Berl) 2001; 156: 435-444.
9. Rush CR, Baker RW, Wright K,. Acute physiological and behavioral effects of oral cocaine in humans: a dose-response analysis. Drug Alcohol Depend 1999; 55: 1-12.
10. Plotkin SA, ed. History of Vaccine Development. New York, Dordrecht, Heidelberg and London: Springer, 2008.
11. Curd J, Smith TW, Jaton JC, Haber E,. The isolation of digoxin-specific antibody and its use in reversing the effects of digoxin. Proc Natl Acad Sci U S A 1971; 68: 2401-2406.
12. Berkowitz B, Spector S,. Evidence for active immunity to morphine in mice. Science 1972; 178: 1290-1292.
13. Bonese KF, Wainer BH, Fitch FW, Rothberg RM, Schuster CR,. Changes in heroin self-administration by a rhesus monkey after morphine immunization. Nature 1974; 252: 708-710.
14. Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR,. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005; 58: 158-164.
15. Martell BA, Orson FM, Poling J, Mitchell E, Rossen RD, Gardner T, Kosten TR,. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double blind, placebo-controlled efficacy trial. Arch Gen Psychiatry 2009; 66: 1116-1123.
16. Kosten TR, Rosen M, Bond J, Settles M, St. Clair Roberts J, Shields J, Jack L, Fox B,. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002; 20: 1196-1204.
17. Haney M, Gunderson EW, Jiang H, Collins ED, Foltin RW,. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry 2010; 67: 59-65.
18. Orson FM, Kinsey BM, Singh RA, Wu Y, Kosten TR,. Vaccines for cocaine abuse. Hum Vaccin 2009; 5: 194-199.
19. McMillan DE, Hardwick WC, Li M, Owens SM,. Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat. J Pharmacol Exp Ther 2004; 309: 1248-1255.
20. Byrnes-Blake KA, Laurenzana EM, Landes RD, Gentry WB, Owens SM,. Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats. Eur J Pharmacol 2005; 521: 86-94.
21. Gentry WB, Laurenzana EM, Williams DK, Owens SM,. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Int Immunopharmacol 2006; 6: 968-977.
22. Hicks MJ, De Bishnu P, Rosenberg JB, Davidson JT, Moreno AY, Janda KD, Wee S, Koob GF, Hackett NR, Kaminsky SM, Worgall S, Toth M, Mezey JG, Crystal RG,. Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs. Mol Ther 2011; 19: 612-619.
23. Marshall E,. Gene therapy on trial. Science 2000; 288: 951-957. doi: 10.1126/science.288.5468.951.
24. Hatsukami DK, Rennard S, Jorenby D,. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 2005; 78: 456-467.
25. Fox BS, Kantak KM, Edwards MA, Black KM, Bollinger BK, Botka AJ, French TL, Thompson TL, Schad VC, Greenstein JL, Gefter ML, Exley MA, Swain PA, Briner TJ,. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 1996; 2: 1129-1132.
26. Pentel PR, Malin DH, Ennifar S,. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 2000; 65: 191-198.
27. Hieda Y, Keyler DE, VanDeVoort JT,. Immunization of rats reduces nicotine distribution to brain. Psychopharmacology 1999; 143: 150-157.
28. Hieda Y, Keyler DE, Vandevoort JT, Pentel PR,. Active immunization alters the plasma nicotine concentration in rats. J Pharmacol Exp Ther 1997; 283: 1076-1081.
29. Ramakrishnan M, De Melo FA, Kinsey BM, Ladbury JE, Kosten TR, Orson FM,. Probing cocaine-antibody interactions in buffer and human serum. PLoS ONE 2012; 7: e40518.
30. Stewart DJ, Inaba T, Lucassen M, Kalow W,. Cocaine metabolism: cocaine and norcocaine hydrolysis by liver and serum esterases. Clin Pharmacol Ther 1979; 25: 464-468.
31. Kamendulis LM, Brzezinski MR, Pindel EV, Bosron WF, Dean RA,. Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J Pharmacol Exp Ther 1996; 279: 713-717.
32. Jenkins AJ, Keenan RM, Henningfield JE, Cone EJ,. Correlation between pharmacological effects and plasma cocaine concentrations after smoked administration. J Anal Toxicol 2002; 26: 382-392.
33. Apicella MA, Murphy TF,. Haemophilus influenzae type b (Hib) vaccine. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions (Fifteenth Edition), 2006, 1569-1572.
34. Li H, Nookala S, Re F,. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1β and IL-18 release. J Immunol 2007; 178: 5271-5276.
35. Pérez-Melgosa M, Ochs HD, Linsley PS, Laman JD, van Meurs M, Flavell RA, Ernst RK, Miller SI, Wilson CB,. Carrier-mediated enhancement of cognate T cell help: the basis for enhanced immunogenicity of meningococcal outer membrane protein polysaccharide conjugate vaccine. Eur J Immunol 2001; 31: 2373-2381.
36. Shen XY, Kosten TA, Lopez AL, Kinsey BM, Kosten TR, Orson FM,. A vaccine against methamphetamine attenuates its behavioral effects in mice. Drug Alcohol Depend 2013; 129: 41-48. PMID: 23022610.
37. Lindroth K, Mastache EF, Roos I, Fernández AG, Fernández C,. Understanding thymus-independent antigen-induced reduction of thymus-dependent immune responses. Immunology 2004; 112: 413-419.